Phase I/II Study to Determine the MTD and to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Antroquinonol in Combination With SOC in First Line Metastatic Pancreatic Cancer
Summary
The purpose of this phase I/II study is to evaluate antroquinonol in combination with nab-paclitaxel and gemcitabine in first line treatment naïve patients with stage IV metastatic pancreatic carcinoma.
General Information
NCT#: NCT03310632
Study ID: GHPanc-1-001
Trial Phase: Phase I/II
Trial Sponsor: Golden Biotechnology Corporation, Covance
Therapies Used in This Trial: Nab-paclitaxel, Gemcitabine, Antroquinonol